These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38767452)
1. Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis. Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Ramamoorthy S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C Cancer Res Commun; 2024 Jun; 4(6):1454-1466. PubMed ID: 38767452 [TBL] [Abstract][Full Text] [Related]
2. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML. Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C J Clin Oncol; 2023 Dec; 41(34):5306-5319. PubMed ID: 37235836 [TBL] [Abstract][Full Text] [Related]
3. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Kakihana K; Fujioka Y; Suda W; Najima Y; Kuwata G; Sasajima S; Mimura I; Morita H; Sugiyama D; Nishikawa H; Hattori M; Hino Y; Ikegawa S; Yamamoto K; Toya T; Doki N; Koizumi K; Honda K; Ohashi K Blood; 2016 Oct; 128(16):2083-2088. PubMed ID: 27461930 [TBL] [Abstract][Full Text] [Related]
4. Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial. Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C Clin Cancer Res; 2023 Dec; 29(23):4920-4929. PubMed ID: 37787998 [TBL] [Abstract][Full Text] [Related]
5. Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature. Biernat MM; Urbaniak-Kujda D; Dybko J; Kapelko-Słowik K; Prajs I; Wróbel T J Int Med Res; 2020 Jun; 48(6):300060520925693. PubMed ID: 32527171 [TBL] [Abstract][Full Text] [Related]
6. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers. Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412 [TBL] [Abstract][Full Text] [Related]
7. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. DeFilipp Z; Peled JU; Li S; Mahabamunuge J; Dagher Z; Slingerland AE; Del Rio C; Valles B; Kempner ME; Smith M; Brown J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Ballen KK; Sung AD; Dalton TE; Messina JA; Dettmer K; Liebisch G; Oefner P; Taur Y; Pamer EG; Holler E; Mansour MK; van den Brink MRM; Hohmann E; Jenq RR; Chen YB Blood Adv; 2018 Apr; 2(7):745-753. PubMed ID: 29592876 [TBL] [Abstract][Full Text] [Related]
8. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601 [TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-versus-host disease due to imbalanced gut microbiota and bile acid metabolism. Han L; Sun X; Kong J; Li J; Feng K; Bai Y; Wang X; Zhu Z; Yang F; Chen Q; Zhang M; Yue B; Wang X; Fu L; Chen Y; Yang Q; Wang S; Xin Q; Sun N; Zhang D; Zhou Y; Gao Y; Zhao J; Jiang Y; Guo R J Transl Med; 2024 Aug; 22(1):746. PubMed ID: 39113144 [TBL] [Abstract][Full Text] [Related]
10. Alteration of Gut Microbiota Composition and Diversity in Acute and/or Chronic Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study. Gavriilaki E; Christoforidi M; Ouranos K; Minti F; Mallouri D; Varelas C; Lazaridou A; Baldoumi E; Panteliadou A; Bousiou Z; Batsis I; Sakellari I; Gioula G Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891979 [TBL] [Abstract][Full Text] [Related]
11. Human gut microbiota-reactive DP8α Tregs prevent acute graft-versus-host disease in a CD73-dependent manner. Godefroy E; Chevallier P; Haspot F; Vignes C; Daguin V; Lambot S; Verdon M; De Seilhac M; Letailleur V; Jarry A; Pédron A; Guillaume T; Peterlin P; Garnier A; Vibet MA; Mougon M; Le Bourgeois A; Jullien M; Jotereau F; Altare F JCI Insight; 2024 Aug; 9(18):. PubMed ID: 39088302 [TBL] [Abstract][Full Text] [Related]
12. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Han L; Zhang H; Chen S; Zhou L; Li Y; Zhao K; Huang F; Fan Z; Xuan L; Zhang X; Dai M; Lin Q; Jiang Z; Peng J; Jin H; Liu Q Biol Blood Marrow Transplant; 2019 Oct; 25(10):1944-1955. PubMed ID: 31299215 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation]. Zheng YY; Yang XT; Lin GQ; Bian MR; Si YJ; Zhang XX; Zhang YM; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):401-407. PubMed ID: 37550190 [No Abstract] [Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease. van Lier YF; Vos J; Blom B; Hazenberg MD Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370 [TBL] [Abstract][Full Text] [Related]
15. Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic hematopoietic stem cell transplantation. Ingham AC; Kielsen K; Cilieborg MS; Lund O; Holmes S; Aarestrup FM; Müller KG; Pamp SJ Microbiome; 2019 Sep; 7(1):131. PubMed ID: 31519210 [TBL] [Abstract][Full Text] [Related]
16. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia. Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100 [TBL] [Abstract][Full Text] [Related]
17. Recipient microbiome-related features predicting metabolic improvement following fecal microbiota transplantation in adults with severe obesity and metabolic syndrome: a secondary analysis of a phase 2 clinical trial. Zhang Z; Mocanu V; Deehan EC; Hotte N; Zhu Y; Wei S; Kao DH; Karmali S; Birch DW; Walter J; Madsen KL Gut Microbes; 2024; 16(1):2345134. PubMed ID: 38685731 [TBL] [Abstract][Full Text] [Related]
18. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders. Biagi E; Zama D; Rampelli S; Turroni S; Brigidi P; Consolandi C; Severgnini M; Picotti E; Gasperini P; Merli P; Decembrino N; Zecca M; Cesaro S; Faraci M; Prete A; Locatelli F; Pession A; Candela M; Masetti R BMC Med Genomics; 2019 Mar; 12(1):49. PubMed ID: 30845942 [TBL] [Abstract][Full Text] [Related]
19. Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study. van Lier YF; Rolling T; Armijo GK; Zhai B; Haverkate NJE; Meijer E; Nur E; Blom B; Peled JU; van den Brink MRM; Hohl TM; Hazenberg MD; Markey KA Transplant Cell Ther; 2023 Jan; 29(1):63.e1-63.e5. PubMed ID: 36280104 [TBL] [Abstract][Full Text] [Related]
20. Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: A case report. Mao D; Jiang Q; Sun Y; Mao Y; Guo L; Zhang Y; Man M; Ouyang G; Sheng L Medicine (Baltimore); 2020 Sep; 99(38):e22129. PubMed ID: 32957333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]